AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06421077 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transauricular auricular vagus nerve stimulation
Description: transauricular auricular vagus nerve stimulation
Study NCT06421077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transauricular auricular vagus nerve stimulation
Description: transauricular auricular vagus nerve stimulation
Study NCT05799326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
Study NCT05799326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin simulant
Description: Levofloxacin simulant is placebo.
Study NCT06084221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data-Driven Decision Making (DDDM)
Description: The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
Study NCT06084221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose-prevention strategies inventory
Description: A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
Study NCT05462834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressed Air
Description: Participants will be instructed to use compressed air during sleep as a placebo control.
Study NCT05462834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
Study NCT06478121 — intervention group
Intervention type: OTHER
Intervention: Data and Blood collection
Description: Data and Blood collection
Study NCT06478121 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI (optional)
Study NCT06000319 — intervention group
Intervention type: BIOLOGICAL
Intervention: Natural Matrix Protein (NMP) Fibers
Description: human bone allograft
Study NCT06000319 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar interbody fusion
Description: Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
Study NCT06000319 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical interbody fusion
Description: Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
Study NCT04836559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 will be administered orally.
Study NCT04836559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-40411813
Description: JNJ-40411813 will be administered orally.
Study NCT04836559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT06768671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Open label
Study NCT05593328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule
Study NCT05593328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
Study NCT05593328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
Study NCT05593328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT05593328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study NCT04959474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard dietary recommendations
Study NCT04959474 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study NCT04959474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study NCT04959474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection
Study NCT04959474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT06646211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib , Thiotepa
Description: First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21
Study NCT06646211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate , Thiotepa and Zanubrutinib
Description: Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21
Study NCT06646211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCT±Zanubrutinib
Description: Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age > 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)
Study NCT06646705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study NCT06584565 — intervention group
Intervention type: OTHER
Intervention: microbiome; metabolomics; proteomics
Description: post-stroke change of microbiome; metabolomics; proteomics
Study NCT05028647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality training
Description: one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
Study NCT05028647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Augmented reality training
Description: one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
Study NCT05645809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MONOFIX® PGCL
Description: An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
Study NCT06665074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: Dosage of endotoxin is 0.8 ng/Kg body Weight
Study NCT05645809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quill Monoderm™
Description: An absorbable suture made of polyglactin used for soft tissue suture.
Study NCT04321915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of intestinal microbiota in autism spectrum desorder
Description: This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
Study NCT06665074 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: Dosage of endotoxin is 0.8 ng/Kg body Weight
Study NCT06665074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline (Placebo)
Description: Volume of saline to be the same as volume of endotoxin
Study NCT06665074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline (Placebo)
Description: Volume of saline to be the same as volume of endotoxin
Study NCT06664970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine or Ruxolitinib combined with Selinexor
Description: 1. The initial dose of Selinexor combined with Azacitidine for the treatment of MDS patients is 40mg QW, adjusted according to blood tests, with the highest dose ≤ 60mg QW.~   Azacitidine: The initial dose is 75 mg/m ², administered subcutaneously or intravenously, with a cycle of 1-7 days and 28 days until ineffective or intolerant.~2. Selinexor combined with Ruxolitinib for the treatment of patients with MPN symptoms: Selinexor dose: 40mg QW; Adjust according to the blood count, with a maximum dose of ≤ 60mg QW.~Initial dose of Ruxolitinib: platelet count>100 × 109/L before enrollment, initial dose is 15 mg BID; Platelets range from 50-100 × 109/L, with an initial dose of 10 mg BID. Until ineffective or intolerant.
Study NCT04959474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT04959474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT04959474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo a caloric restriction diet
Study NCT04959474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04959474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06259903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: Subcutaneous Administration of MD-18 in Healthy Subjects.
Study NCT04959474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04959474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05986864 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
Study NCT04321915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of neuroinflammation markers in autism spectrum desorder
Description: This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
Study NCT04785573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mastiha oil
Description: 1 soft gel capsule of Mastiha oil every day for 3 months
Study NCT06132906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic surgery (lefort1)
Description: 1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure
Study NCT06132906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery (lefort1)
Description: 1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure
Study NCT05674890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SmartSystem VR Headset perimeter
Description: Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
Study NCT06443541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity implementation strategies (HIS)-Students
Description: Students in the HIS group will receive educational outreach in a pre-implementation in-person orientation to GlobalConsent, covering similar topics and three monthly one-hour learning sessions during implementation in which technical questions about program access or progression can be addressed; more intensive intervention to enhance adherence with more frequent email/Short Message Service (SMS), completion reminders; and demand generation encouraging program completion.
Study NCT06443541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity implementation strategies (LIS) for Students
Description: Students in the LIS group will receive basic implementation strategies of the GlobalConsent often used to deliver online programs at US universities with email/SMS completion reminders with a predetermined frequency for 12 weeks.
Study NCT06443541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity implementation strategies (HIS) for Faculty
Description: * Passive access to web-based educational materials~* Town halls (3) with general faculty to define sexual violence; rates in young people; acute/chronic effects over the life course; primary-prevention evidence-based interventions (EBIs)
Study NCT06443541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity implementation strategies (LIS) for Faculty
Description: Passive access to web-based educational materials
Study NCT06443541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity implementation strategies (HIS) for Leaders
Description: * Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials~* Monthly emails from trained internal facilitators to university leaders with updates on implementation progress~* One post-implementation webinar to share anonymized findings (by IS group); discuss plan for sustainment (including guidance on how to handle reporting of sexual violence in existing university counseling centers)
Study NCT06443541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity implementation strategies (LIS) for Leaders
Description: * Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials
Study NCT06443541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity implementation strategies (HIS) for Implementation Team Members
Description: * Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual~* In-person leadership training to champion GlobalConsent with internal stakeholders (leaders, implementation teams, faculty, students); leadership styles; managing teams; influence without authority; managing conflict; emotional intelligence; negotiation; leading change~* Biweekly (six) 1-hr recorded quality-improvement team webinars to provide refresher training; assess implementation progress; assess modifications; build peer-network; provide anonymized data on implementation progress for discussion
Study NCT05590988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet-based training
Description: Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit.
Study NCT05590988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergotherapeutic training
Description: A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
Study NCT05009394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Muscle Reinnervation (TMR)
Description: Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
Study NCT05009394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenerative Peripheral Nerve Interface (RPNI)
Description: Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
Study NCT05009394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard neuroma treatment, neuroma excision, and muscle burying
Description: Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
Study NCT05382936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-901
Description: Patients took study medication daily, with dosage based on their assigned cohort and regimen.
Study NCT05756608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI and 18F-AlF-FAPI PET-MR
Description: Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
Study NCT06491823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech
Study NCT06203275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
Study NCT06203275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
Study NCT06443541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity implementation strategies (LIS) Implementation Team Members
Description: * Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual
Study NCT06491823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation baseline
Description: Auditory baseline in speech
Study NCT06491823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor evoked potentials
Description: motor evoked potentials will be obtained in each recording block
Study NCT06491823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials
Description: auditory evoked potentials will be obtained in each recording block
Study NCT06491823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials
Description: Somatosensry evoked potentials will be obtained in each recording block
Study NCT05889052 — intervention group
Intervention type: DRUG
Intervention: Sulfadoxine pyrimethamine
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
Study NCT05140291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: 1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes.
Study NCT05140291 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
Study NCT03924778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: brief description